(NASDAQ: ADAG) Adagene's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.46%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.65%.
Adagene's earnings in 2026 is -$17,609,413.On average, 9 Wall Street analysts forecast ADAG's earnings for 2026 to be -$33,229,148, with the lowest ADAG earnings forecast at -$41,794,094, and the highest ADAG earnings forecast at -$22,389,693. On average, 8 Wall Street analysts forecast ADAG's earnings for 2027 to be -$35,041,647, with the lowest ADAG earnings forecast at -$44,696,462, and the highest ADAG earnings forecast at -$27,987,117.
In 2028, ADAG is forecast to generate -$38,465,256 in earnings, with the lowest earnings forecast at -$45,857,409 and the highest earnings forecast at -$24,877,437.